Genetic Alterations in Signaling Pathways in Melanoma
Open Access
- 1 April 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (7), 2301s-2307s
- https://doi.org/10.1158/1078-0432.ccr-05-2518
Abstract
Alterations in the RAS signaling cascade are almost uniformly present in melanoma. RAS itself is only infrequently mutated in melanoma although downstream of RAS lie BRAF on the mitogen-activated protein kinase pathway and PTEN on the protein kinase B/Akt pathway. These genes are often altered in melanomas; indeed, the most frequent target of mutation in melanomas is BRAF, which is mutated in ∼60% to 70% of superficial spreading melanomas. These mutations occur in a background that is not normal, with the CDKN2A locus also typically being mutated. We review herein the data that suggest that the distribution of the signaling mutations is important. In general, melanomas carry a mutated NRAS, a mutated BRAF, or concurrent BRAF and PTEN mutations. These data support the hypothesis that the biochemical functions of RAS are portioned by mutations in the pathways lying downstream. Moreover, these mutations have no apparent relationship to the patterns of alteration of CDKN2A and its downstream effectors. Thus, the data also suggest that successful exploitation of mutations in melanoma will be dependent on understanding not only mutations and their frequency but their genetic context as well.Keywords
This publication has 33 references indexed in Scilit:
- Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous MelanomaJournal of Investigative Dermatology, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Absence of exon 15BRAF germline mutations in familial melanomaHuman Mutation, 2003
- An old kinase on a new path: Raf and apoptosisCell Death & Differentiation, 2002
- Identification of PTEN mutations in metastatic melanoma specimensJournal of Medical Genetics, 2000
- Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma BiopsiesJournal of Investigative Dermatology, 2000
- The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cellsOncogene, 1999
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998
- Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell linesOncogene, 1998
- Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma—an effective combination with unexpected toxicityEuropean Journal Of Cancer, 1992